BTIG lowered the firm’s price target on Evolent Health (EVH) to $20 from $29 but keeps a Buy rating on the shares. The firm notes it was disappointed by the company’s comments around higher ...

Evolent Health (NYSE:EVH) rose 1.3% after activist investor Engaged Capital reached a cooperation agreement with the healthcare services company. Evolent (NYSE:EVH) will add Brendan Springstubb to ...

These figures are anticipated to form a baseline EBITDA of approximately $95 million for the full year 2025. In other recent news, Evolent Health has experienced a series of significant developments.

TD Cowen analyst Charles Rhyee assigned a Buy rating on Evolent Health (EVH – Research Report) today and set a price target of $14.00.Invest ...

R Squared Ltd bought a new position in shares of Evolent Health, Inc. (NYSE:EVH – Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and ...

Citi lowered the firm’s price target on Evolent Health (EVH) to $18 from $21 and keeps a Buy rating on the shares as part of a 2025 outcook for the health technology and distribution group.

13 analysts have shared their evaluations of Evolent Health EVH during the recent three months, expressing a mix of bullish and bearish perspectives. In the table below, you'll find a summary of ...